Bioatla Inc BCAB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:52 AM EDT
7.78quote price arrow up+0.08 (+1.04%)
Volume
33,630
52 week range
2.01 - 31.25
Loading...
  • Open7.71
  • Day High7.97
  • Day Low7.43
  • Prev Close7.70
  • 52 Week High31.25
  • 52 Week High Date11/04/21
  • 52 Week Low2.01
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap291.91M
  • Shares Out37.52M
  • 10 Day Average Volume0.44M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-60.16

KEY STATS

  • Open7.71
  • Day High7.97
  • Day Low7.43
  • Prev Close7.70
  • 52 Week High31.25
  • 52 Week High Date11/04/21
  • 52 Week Low2.01
  • 52 Week Low Date05/09/22
  • Market Cap291.91M
  • Shares Out37.52M
  • 10 Day Average Volume0.44M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-60.16

RATIOS/PROFITABILITY

  • EPS (TTM)-2.73
  • P/E (TTM)-2.85
  • Fwd P/E (NTM)-2.38
  • EBITDA (TTM)-99.289M
  • ROE (TTM)-58.01%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-40,382.00%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/14/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Bioatla Inc

 

Profile

MORE
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidate includes BA3011 (Mecbotamab vedotin), BA3021 (Ozuriftabmab vedotin) and BA3071 (Ozuriftabmab vedotin). The Company’s lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL that is protein kinase receptor. BA3021 is developing a...
Jay Short Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Scott Smith
President, Director
Richard Waldron
Chief Financial Officer, Senior Vice President
Christian Vasquez CPA
Vice President - Finance, Corporate Controller, Secretary
Address
11085 Torreyana Road
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
BMEA
Biomea Fusion Inc
10.30+0.52+5.29%
CBAY
Cymabay Therapeutics Inc
3.50UNCHUNCH
OTLK
Outlook Therapeutics Inc
1.24+0.02+1.64%
VXRT
Vaxart Inc
2.17UNCHUNCH
OPT
Opthea Ltd
6.19-0.01-0.16%